Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 May;141(5):615-21.
doi: 10.1111/j.1365-2141.2008.07086.x. Epub 2008 Mar 27.

The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma

Clive S Zent  1 , Wei Ding, Susan M Schwager, Megan S Reinalda, James D Hoyer, Diane F Jelinek, Renee C Tschumper, Deborah A Bowen, Timothy G Call, Tait D Shanafelt, Neil E Kay, Susan L Slager
Affiliations

The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma

Clive S Zent et al. Br J Haematol. 2008 May.

Abstract

The development of cytopenia in chronic lymphocytic leukaemia (CLL) patients can predict poor prognosis. All CLL patients seen in the Division of Hematology at Mayo Clinic Rochester from 1 January 1995 to 31 December 2004 (n = 1750) were evaluated for cytopenia, aetiology of cytopenia and clinical outcome. Cytopenia occurred in 423 (24.2%) patients and was attributable to CLL in 303 (17.3%) cases, with 228 (75%) of these having bone marrow (BM) failure and 75 (25%) having autoimmune disease (AID). Survival from onset of cytopenia was significantly better for patients with AID (median 9.1 years) compared to patients with BM failure (median 4.4 years, P < 0.001). Patients with AID diagnosed within 1 year of the diagnosis of CLL (n = 35) had similar survival from diagnosis compared to patients without CLL-related cytopenia (median 9.3 vs. 9.7 years, P = 0.881). Although cytopenia caused by BM failure predicted a poorer prognosis in CLL, cytopenia caused by AID was not an adverse prognostic factor. These findings suggest that patients with cytopenia due to AID cannot be meaningfully classified by the current clinical staging systems. Revisions of the National Cancer Institute Working Group 96 criteria should consider the aetiology of cytopenia in staging CLL patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Survival from Diagnosis of Cytopenia
Patients with cytopenia caused by autoimmune complications of CLL (AID) had a significantly better survival (median 9.1 years) than patients with cytopenia caused by bone marrow failure (BM failure) (median 4.4 years)
Figure 2
Figure 2. Survival from Diagnosis of CLL
a. Patients with autoimmune cytopenia (AID) had better survival from diagnosis of CLL (median 12.4 years) than patients without cytopenia (median 9.7 years). b. Patients with AID diagnosed within 1 year of their CLL (AID < 1 year) had equivalent survival (median 9.3 years) compared to patients without cytopenia.
Figure 2
Figure 2. Survival from Diagnosis of CLL
a. Patients with autoimmune cytopenia (AID) had better survival from diagnosis of CLL (median 12.4 years) than patients without cytopenia (median 9.7 years). b. Patients with AID diagnosed within 1 year of their CLL (AID < 1 year) had equivalent survival (median 9.3 years) compared to patients without cytopenia.
Figure 3
Figure 3. Survival in CLL Patients with Bone Marrow Failure
a. Patient survival from cytopenia was better for presentation with cytopenia (median 6.2 years) compared to later BM failure (median 3.9 years). b. Patient survival from CLL diagnosis was better with later BM failure (median 10.4 years) compared to presentation with BM failure (median 6.2 years).
Figure 3
Figure 3. Survival in CLL Patients with Bone Marrow Failure
a. Patient survival from cytopenia was better for presentation with cytopenia (median 6.2 years) compared to later BM failure (median 3.9 years). b. Patient survival from CLL diagnosis was better with later BM failure (median 10.4 years) compared to presentation with BM failure (median 6.2 years).
See this image and copyright information in PMC

References

    1. Apelgren P, Hasselblom S, Werlenius O, Nilsson-Ehle H, Andersson P-O. Evaluation of clinical staging in chronic lymphocytic leukemia - a population based study. Leukemia and Lymphoma. 2006;47:2505–2516. - PubMed
    1. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbes S, Gremy F. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198–205. - PubMed
    1. Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, Shepherd L, Hines JD, Schiffer CA, Larson RA. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105:49–53. - PubMed
    1. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood. 1996;87:4990–4997. - PubMed
    1. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marce S, Lopez-Guillermo S, Campo E, Montserrat E. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. NewEngland Journal of Medicine. 2003;348:1764–1775. - PubMed

Publication types